Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biocryst Pharma Inc (NQ: BCRX )

7.750 +0.020 (+0.26%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,205,529
Open 7.760
Bid (Size) 7.700 (8)
Ask (Size) 8.200 (1)
Prev. Close 7.730
Today's Range 7.570 - 7.800
52wk Range 4.030 - 8.880
Shares Outstanding 185,583,896
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Rapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market
EQNX::TICKER_START (NYSE:NNVC),(NASDAQ:BCRX),(NASDAQ:VERU),(NASDAQ:CMRX),(NASDAQ:SIGA) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures COVID-19
BioCryst Pharmaceuticals (BCRX) Q2 2024 Earnings Call Transcript
BCRX earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial

Performance

YTD
+27.68%
+27.68%
1 Month
+0.26%
+0.26%
3 Month
+23.02%
+23.02%
6 Month
+50.78%
+50.78%
1 Year
+11.67%
+11.67%

More News

Read More
7 Small-Cap Stocks to Buy for Large-Scale Gains
Via InvestorPlace
A Preview Of BioCryst Pharma's Earnings
Via Benzinga
What's Going On With BioCryst Pharmaceuticals Stock?
Via Benzinga
Where BioCryst Pharma Stands With Analysts
Via Benzinga
What 7 Analyst Ratings Have To Say About BioCryst Pharma
Via Benzinga
Rapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market
From FN Media Group LLC
Via GlobeNewswire
3 Insider-Buy Stocks to Add to Your Watchlist Now
Via MarketBeat
Why Bolt Biotherapeutics Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
NEXTracker Posts Upbeat Earnings, Joins monday.com, Nu Holdings And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Why BioCryst Pharmaceuticals Vaulted Nearly 20% Higher on Monday
Via The Motley Fool
BioCryst Pharmaceuticals 'Fantastic' Q1 Earnings Rides On Outstanding Orladeyo Performance
Via Benzinga
BioCryst Pharmaceuticals (BCRX) Q1 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Why Perficient Shares Are Trading Higher By Around 53%? Here Are 20 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
BCRX Stock Earnings: BioCryst Pharma Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Hidden Penny Gems: 7 Stocks With Triple-Digit Growth Prospects
Via InvestorPlace
BioCryst Pharmaceuticals (BCRX) Q4 2023 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
What's Going On With BioCryst Stock After Earnings?
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Li Auto Posts Q4 Earnings, Joins Teva Pharmaceutical And Other Big Stocks Moving Higher In Monday's Pre-Market Session
Via Benzinga
Topics Stocks
Exposures US Equities
Earnings Scheduled For February 26, 2024
Via Benzinga
Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Why AeroVironment Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
BioCryst Pharmaceuticals (BCRX) Q3 2023 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.